Analysis of ALK gene in 133 patients with breast cancer revealed polysomy of chromosome 2 and no ALK amplification

ALK has emerged as a novel tumorigenic factor in several epithelial human cancers. Crizotinib, an ALK tyrosine kinase inhibitor, is currently approved to treat lung cancer patients exhibiting ALK gene rearrangements. Our goal was to determine the incidence of ALK aberrations in relation to different...

Descripción completa

Detalles Bibliográficos
Autores principales: Hanna, Matthew G., Najfeld, Vesna, Irie, Hanna Y., Tripodi, Joseph, Nayak, Anupma
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2015
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4544610/
https://www.ncbi.nlm.nih.gov/pubmed/26312204
http://dx.doi.org/10.1186/s40064-015-1235-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4544610/
https://www.ncbi.nlm.nih.gov/pubmed/26312204
http://dx.doi.org/10.1186/s40064-015-1235-9

Ejemplares similares